Clinical Trials Directory

Trials / Unknown

UnknownNCT00192803

Non-Insulin Dependent Diabetes Mellitus (NIDDM) and Angiotensin Converting Enzyme 2 (ACE2): Diabetic Patients Treated With Antihypertensive Drugs

ACE/ACE2 Ratio in Diabetic Patients Treated With Antihypertensive Drugs

Status
Unknown
Phase
Phase 4
Study type
Interventional
Enrollment
20 (planned)
Sponsor
Rambam Health Care Campus · Academic / Other
Sex
All
Age
18 Years – 90 Years
Healthy volunteers
Not accepted

Summary

This feasibility study is designed to examine modulation of the relative activities of ACE and ACE2 in diabetic patients following treatment with the angiotensin type 1 receptor (AT1R) antagonist, Candesartan. This study will provide a closer insight to the possible involvement of the renin-angiotensin system (RAS)-related enzymatic components in development or attenuation of vascular pathogenesis.

Conditions

Interventions

TypeNameDescription
DRUGcandesartan

Timeline

First posted
2005-09-19
Last updated
2006-02-23

Locations

1 site across 1 country: Israel

Source: ClinicalTrials.gov record NCT00192803. Inclusion in this directory is not an endorsement.